|Articles|March 22, 2023

TrakCel and Lonza Reach Integration Milestone to Combine Cell and Gene Therapy Manufacturing, Orchestration Solutions

The combined solutions are currently available on the market.

TrakCel announced on March 17, 2023 that their collaboration with Lonza has reached a new milestone, resulting in a secure, reliable combination of TrakCel’s cell orchestration platform OCELLOS and Lonza’s manufacturing MODA-ES(R) platform. This integration will translate into critical manufacturing steps, checks, and data flow directly into the Chain of Custody and Chain of Identity within the cell and gene therapy supply chain without the opportunity of being missed or not connecting with the patient journey.

For developers, this will assist in them gaining additional visibility and control while reducing product loss, delayed treatment, recalls, and poor-quality product. The combined solutions are currently available on the market.

The collaboration between TrakCel and Lonza includes a multi-phase rollout of connectivity with OCELLOS to other Lonza systems like SAP and LIMs. Other integrations are planned to follow the MES proof of concept and are likely to be completed in the second half of 2023.

Source: TrakCel

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

Global shipping and supply chain vector illustration. Abstract concept with world map background and connected icons related to international import / export, distribution and transportation. | Image credit: © j-mel - © j-mel - stock.adobe.com

September 17th, 2026

FDA, Genentech, Minaris Panelists Detail Raw Material Risk Strategies for Advanced Therapies

Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.

T-Cells Work to Fight Cancer, Immunotherapy, CAR T-cell therapy, 3d rendering | Image credit: © Design Cells - © Design Cells - stock.adobe.com

September 22nd, 2026

Made Scientific Adds 85,000 Sq. Ft. Cell Therapy GMP Site

Made Scientific's new 85,000-sq.-ft. facility, with 145 prior GMP batches, adds clinical- to commercial-scale cell therapy capacity.

3D illustration of a bispecific antibody molecule connecting a blue T-cell to a red target cell, with additional antibody molecules visible in the surrounding space. | Image Credit: © Alpha Tauri 3D - stock.adobe.com

September 21st, 2026

Vironexis's One-Time In Vivo Therapy Drives Complete Responses in Relapsed ALL

Vironexis Biotherapeutics reported that the first three antibody-naive patients with relapsed/refractory acute lymphoblastic leukemia treated with its one-time in vivo immunotherapy VNX-101 all achieved MRD-negative complete responses, with durability tracked through at least nine months.

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com

September 14th, 2026

As Companies Flee Ex Vivo Cell Therapy, Even Automated Manufacturing Platforms Face Validation Hurdles

Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.